Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Wednesday, December 13, 2017
Samsung BioLogics has been licensed by the Europe’s EMA for the first monoclonal antibody Drug Substance at its second plant.
read more
Samsung Biologics announced that the company was awarded the EcoVadis' Platinum Sustainability Rating, the highest recognition given, for the company's sustainability management.
read more
Samsung BioLogics announced today that a third monoclonal antibody Drug Substance has been licensed by the FDA for its second plant.
read more
Samsung Biologics signed an agreement with the Incheon Free Economic Zone (IFEZ) on July 18th to build out its second Bio Campus.
read more
Samsung BioLogics announced on October 1st, 2018 that its Plant 3 has become cGMP ready and started production (OOF, out of freezing) after its successful validation.
read more
Samsung Biologics has successfully renewed its ISO 27001 certification (Information Security Management System) and obtained ISO 27017 certification (Information Security in cloud services) and ISO 37001 certification (Anti-bribery management systems...
read more
Wednesday, December 30, 2020
Samsung Biologics announced John Rim as its President and CEO.
read more
Samsung Biologics, a world-leading contract development and manufacturing organization (CDMO), is launching its new proprietary development technology platforms – S-DUAL™ and DEVELOPICK™ – at this year's BioProcess International Conference and ...
read more
Samsung Biologics, a contract development and manufacturing organization (CMDO), celebrated the one-year mark of Live Virtual Tour (LVT), a platform to provide remote site inspections for clients and regulatory agencies. The tool was developed and ...
read more
Samsung BioLogics has successfully performed N-1 (3,000L) perfusion with Alternating Tangential Flow device to supply the 15,000L commercial production process in the Plant 3 facility at its manufacturing site in Songdo, S. Korea.
read more
Monday, February 24, 2020
Samsung Biologics has been monitoring the COVID-19 situation closely since the initial outbreak in late January and taking proactive measures company-wide to ensure a safe working environment and continuous business operations.
read more
Tuesday, November 28, 2023
Samsung Biologics, a prominent global contract development and manufacturing organization (CDMO), hosted its inaugural Suppliers ESG Day at its Songdo headquarters and online, marking a significant step toward sharing environmental, social, and ...
read more
Monday, December 14, 2020
Samsung Biologics officially began construction of its Plant 4 in Incheon, South Korea.
read more
Thursday, October 23, 2025
Samsung Biologics announced a shareholder-approved split of its business divisions, positioning itself as a pure-play contract development and manufacturing organization (CDMO). The move, passed with 99.9% approval at an extraordinary shareholders’ ...
read more
Samsung Biologics entered into a strategic partnership with PharmAbcine for the development and manufacturing of PMC-402 pipeline.
read more